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Abstract: Increased levels of calprotectin subunits S100A8 and S100A9 have been detected in human cancers. Melanoma is the most
aggressive type of skin cancer, and its treatment is challenging because of its brain metastasis. OCLN encodes occludin, which plays
a major role in the formation and regulation of tight junctions. The aim of this study was to evaluate the methylation status of the
OCLN promoter and its expression in A-375 melanoma cells treated with or without various concentrations of S100A9 for 24, 48, and
72 h. Total RNA was extracted, and synthesized cDNA was assessed by performing real-time PCR. MSP-PCR was performed after
treatment with bisulfite. Recombinant S100A9 inhibited the proliferation of the A-375 cell line and the expression of the OCLN gene
was downregulated in a time- and concentration-dependent manner. Results of MSP-PCR showed that the OCLN gene promoter in a
human melanoma cell line (A-375) was semimethylated.
Key words: Melanoma, OCLN, calprotectin subunit S100A9, methylation, promoter

1. Introduction
The S100 protein family includes >20 low-molecularweight intracellular proteins containing an EF-hand
motif and showing calcium-binding properties (Donato,
2001). A recent study showed that S100 proteins play
important roles in cancer malignancy and metastasis
(Donato, 2003). Most S100 proteins perform several
intracellular and extracellular functions. Intracellular
functions of S100 proteins include regulation of calcium
homeostasis, cell cycle, cell growth, and cell migration
and regulation and phosphorylation of transcriptional
factors. Extracellular function of S100 proteins is activated
by the binding of tumor necrosis α (TNF-a), interleukin-1
(IL-1), IL-6, chemokines, matrix metalloproteinases
(MMPs), angiogenesis factors, and antiapoptotic proteins
as cytokines to cell surface receptors (Chen et al., 2014).
Three receptor types recognize S100 proteins, namely the
receptor for advanced glycation end products (RAGE),
Toll-like receptors (TLRs), and the extracellular MMP
inducer (EMMPRIN) (Hiratsuka et al., 2008). RAGE is
a multiligand receptor belonging to the immunoglobulin
* Correspondence: ngheibi@qums.ac.ir

superfamily that is involved in inflammation, diabetes,
atherosclerosis, nephropathy, neurodegeneration, and
cancer (Sorci et al., 2004). S100A9, a member of the
S100 protein family, interacts with RAGE, TLRs, and
EMMPRIN (Sakaguchi et al., 2011). EMMPRIN is a
well-known cell surface molecule associated with cancer
cell malignancy (Gabison et al., 2005). The binding of
S100A9 to EMMPRIN provides new insight into the
molecular mechanism underlying S100A9–EMMPRINmediated inflammation and melanoma cancer cell
metastasis (Sakaguchi et al., 2011). EMMPRIN is also
involved in fetal development, retinal function, nervous
system development, and plaque formation in Alzheimer
disease (Iacono et al., 2007). S100A9 is mainly expressed
in myeloid cells and performs a key role in these cells
under inflammatory conditions (Urban et al., 2009). In
humans, serum levels of S100A9 increase during several
disease conditions, including acute inflammatory lesions,
cystic fibrosis, rheumatoid arthritis, and amyloids in the
aging prostate gland (Vogl et al., 2012). Melanoma is
the most aggressive type of skin cancer, involving a type
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of skin cells called melanocytes (Nylund et al., 2012).
Mutations, chemical agents, and aberrant epigenetic
alterations are among the several risk factors of cancers
(Lee et al., 2012). DNA methylation, histone modification,
nucleosome remodeling, and RNA-mediated targeting
regulate many biological processes that are fundamental
to the pathogenesis of cancer (Dawson et al., 2012). Global
hypomethylation is commonly observed in malignant
cells (Azad et al., 2013). The best-studied epigenetic
alterations in cancer cells are methylation changes
occurring within CpG islands, which are present in ∼70%
of all mammalian promoters. CpG island methylation
plays an important role in transcriptional regulation and
is commonly altered during malignant transformation
(Baylin et al., 2011). Aberrant DNA methylation is one of
the epigenetic alterations occurring in the promoters of
tumor suppressor genes and oncogenes (Yang et al., 2011).
DNA methylation is a heritable epigenetic modification
that occurs mostly at CpG dinucleotides, except CpGs
in CpG islands (Weber et al., 2005). DNA methylation
is induced by DNA-cytosine methyltransferase-1. CpG
islands are generally unmethylated in normal adult
tissues, except CpG islands in transcriptionally silent
genes in the inactive X-chromosome and in imprinted
genes (Ducasse et al., 2006). Tight junctions (TJs) are
major structures of endothelial cells in brain capillary
walls that regulate the diffusion of ions, nutrients, and
cells into the brain and cerebrospinal fluid (Hirase et al.,
2001). A family of proteins called claudins are the most
important components of TJs. Twenty-four claudins have
been identified to date. Genes encoding different claudins,
namely CLDN2, CLDN3, CLDN4, CLDN11CL, CLDN12,
CLDN14, and CLDN15, are located on chromosome 7.
OCLN, a TJ gene located on chromosome 5 (cytogenetic
band 5q13.2), encodes occludin, which plays an important
role in the formation and regulation of TJs (Gabison et al.,
2005; Rachow et al., 2013). Occludin induces adhesion
when expressed in cells lacking TJs (Yashin et al., 2013).
Occludin contains a long cytoplasmic domain rich in
serine, threonine, and tyrosine, and phosphorylation
levels of serine and threonine residues of occludin are
strongly correlated with TJ formation. Occludin directly
associates with cytoplasmic scaffolding proteins such as
zona occludens-1, a submembrane component of TJs, thus
directly associating with the actin cytoskeleton (Osanai et
al., 2006). Disruption of the TJ structure is associated with
cancer development, invasion, and metastasis to distant
sites (Tobioka et al., 2006). Conversely, overexpression
of TJ-related proteins such as claudin-1 and claudin-4
in cancer cells induces apoptosis and suppresses the
metastatic potency of these cells (Osanai et al., 2006). At
present, no effective treatment is available for treating
melanoma, and early diagnosis and chemotherapy are
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the only options for treating patients with this cancer
(Sgambato et al., 2010). The present study investigated
OCLN expression level in melanoma cell line A-375
treated with and without calprotectin subunit S100A9.
Moreover, this study assessed the methylation status of the
OCLN promoter in A-375 melanoma cells treated with and
without recombinant S100A9.
2. Methods and materials
2.1. Materials
Isopropyl β-d-1-thiogalactopyranoside (IPTG) (1
mM), Ni-NTA resin, Tris, acrylamide, bacterial and
media (LB broth) were purchased from Sigma-Aldrich
(Germany). Ampicillin was purchased from Roche, and
sodium chloride (NaCl), sodium dihydrogen phosphate
(NaH2PO4), calcium chloride (CaCl2), and imidazole were
obtained from AppliChem. Competent Escherichia coli
strain BL21 (DE3) and the N-terminal S100A9 coding
sequence were provided by Novagen. Human melanoma
cell line A-375 (NCBI No. Index: C-136) was obtained
from the Pasteur Institute of Iran. Chemicals, culture
media, and related compounds were purchased from
GIBCO Co. Cell viability was measured by performing
the
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2Htetrazolium bromide (MTT) assay. RNA was extracted
using a GeneAll kit (Ribospin Cat. No. 04-150), and cDNA
was synthesized using a first-strand cDNA synthesis kit
(Thermo Scientific). Real-time PCR was performed using
SYBR Green master mix (TAKARA BIO INC., Cat No.
RR820Q) and the ABI StepOne qRT-PCR system.
2.2. Methods
2.2.1. Transformation, expression, and purification of
S100A9 protein
After transformation of the pET15b vector including the
his-tagged S100A9 gene to the Escherichia coli BL21 (DE3)
host cells, the expression of S100A9 protein was induced
by 1 mM IPTG. The expressed S100A9 was purified by
performing Ni-NTA affinity chromatography and verified
as reported in our previous study (Asghari et al., 2016).
Purified his-tagged r-S100A9 was observed with the SDSPAGE analysis technique.
2.2.2. Cell culture and cell viability measurement
A-375 melanoma cells were cultured in high-glucose
DMEM supplemented with 15% fetal bovine serum, 100
U/mL penicillin, and 100 g/mL streptomycin at 37 °C in
a humidified CO2 incubator with an atmosphere of 5%
CO2 and 95% air. Cell cultures were examined regularly.
The MTT assay was performed using cells in three 96-well
plates incubated for 24, 48, and 72 h. The cells were cultured
overnight at a density of 8000 cells/well in culture medium
to attach the plate. Next, the medium was replaced with a
medium containing different concentrations (2.5, 5, and
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7.5 µM) of S100A9, and the cells were incubated for 24,
48, and 72 h.
2.3. RNA extraction and first-strand cDNA synthesis
Total RNA was extracted from 1 × 105 A-375 cells treated
with S100A9 by using the GeneAll kit (Cat. No. 305-106),
and the quality of the extracted RNA was determined by
performing gel electrophoresis. An equal amount of RNA
(100 ng) from each sample was added to 25 µL of reaction
mixture, and cDNA was synthesized using a first-strand
cDNA synthesis kit and M-MuLV reverse transcriptase
(Thermo Scientific). The quality of the synthesized cDNA
was assessed by performing NanoDrop spectroscopy and
gel electrophoresis.
2.4. Real-time PCR
To examine the effects of S100A9 on OCLN expression, we
treated A-375 cells with 3 concentrations (2.5, 5, and 7.5
µM) of S100A9 for 24, 48, and 72 h. Real-time PCR was
performed after extracting RNA from the treated A-375
cells and synthesizing first-strand cDNA. Primers for qRTPCR were obtained from Tag Copenhagen A/S (Denmark).
Sequences of primers for the human OCLN cDNA are
as
follows:
5′-GACTTCAGGCAGCCTCGTTAC-3′
(forward) and 5′-GCCAGTTGTGTAGTCTGTCTCA-3′
(reverse). Tm of the forward primer was 56.3 °C and
that of the reverse primer was 54.8 °C. Glyceraldehyde
3-phosphate dehydrogenase (GAPDH) was used as an
internal control. Primer sequences for GAPDH are as
follows: 5′-CAATGACCCCTTCATTGACC-3′ (forward)
and 5′-AATCCCATCACCATCTTCCA-3′ (reverse). The
PCR protocol was as follows: initial denaturation at 95 °C
for 5 min, followed by 40 cycles of denaturation at 95 °C for
20 s and annealing and extension at 60 °C for 60 s. Relative
gene expression was calculated using the comparative CT
method (Schmittgen et al., 2008). GAPDH expression was
used to calculate the delta CT value and to determine the
fold change compared with gene expression in control
cells (untreated A-375 melanoma cells). Gene expression
was determined using the ABI StepOne Real-Time PCR
system and SYBR Green master mix and was analyzed
using the Pfaffl method and GraphPad Prism v6.07
software. All trials were done triplicate.
2.5. DNA extraction and methylation-specific PCR
A-375 cells were harvested at 24, 48, and 72 h after S100A9
treatment. Genomic DNA was extracted using the MiniBEST
Universal Genomic DNA Extraction Kit, and DNA
concentration was assessed using a NanoDrop ND-1000
spectrophotometer. The extracted DNA was modified using
sodium bisulfite with the EpiTect Bisulfite Kit (QIAGEN,
Germany), according to the manufacturer’s instructions.
Primers for methylation-specific PCR (MSP-PCR) were
as follows: (1) 5′- AGTATCGAACGTATTTCGGGG-3′
and
5′-GCGCTCACCTAACGAACGCA-3′
for
amplifying
methylated
alleles
and
(2)

5′-AGTTTTAGGTGAATTGGTTATTGAG-3′
and
for
5′-ACAACCTTAATCTACCAAACTCAAA-3′
amplifying unmethylated alleles. MSP-PCR of the sodium
bisulfite-modified DNA was performed to determine the
methylation status of CpG islands in the OCLN promoter.
MSP-PCR was performed using the following thermal
cycling conditions: initial denaturation at 95 °C for 15 min,
followed by 40 cycles of denaturation at 95 °C for 20 s and
annealing and extension at 58 °C for 45 s.
2.6. Statistical analysis
Statistical analysis was performed using the Pfaffl method
and GraphPad Prism v. 6.07. Data are presented as mean ±
SD. P < 0.05 was considered significant.
3. Results
3.1. Recombinant S100A9 expression and purification
Expressed recombinant S100A9 had an apparent molecular
weight of approximately 14 kDa compared with the
logarithmic molecular weights of standard marker proteins
(Figure 1). Results of the protein assay indicated that the
expression yield of recombinant S100A9 was equal to 0.07
mg/mL.
3.2. Proliferation assay after cells’ treatment with S100A9
We treated A-375 human melanoma cells with various
concentrations (2.5, 5, 7.5, and 10 µM) of S100A9 for 24,
48, and 72 h and assessed their viability by MTT assay. The
IC50 values of S100A9 after treatment for 24, 48, and 72 h
were 12.5, 6.9, and 5.3 µM, respectively.
3.3. Expression of OCLN
The expression of OCLN in S100A9-treated A-375 cells with
three concentrations (2.5, 5, and 7.5 µM) for 24, 48, and
72 h was compared with that in untreated control A-375
cells and the internal control, GAPDH. In Figure 2, the
melting curves obtained for internal control (GAPDH) and
the OCLN gene are 89.3 °C and 82.73 °C, respectively. The
expression ratio after standardization (fold change) of the
OCLN gene is illustrated in Figure 3. The expression gene
of samples (treated) was gradually decreased relative to the
control (without treatment) in a time- and concentrationdependent manner.
3.4. Methylation status of the OCLN promoter
We also assessed the methylation status of the OCLN
promoter. A-375 melanoma cells were treated with different
concentrations of S100A9 for different times. Next, the cells
were harvested, and their DNA was extracted. As illustrated
in Figures 4 and 5 the MSP-PCR was performed after
treating the extracted DNA with bisulfate. Results of MSPPCR showed that the OCLN promoter was semimethylated.
4. Discussion
Results of the present study showed that the viability of
A-375 melanoma cells decreased after treatment with
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Figure 1. SDS-PAGE of purified S100A9 subunit of calprotectin (S100A9). S100A9
sequences were inserted in the vector (pET15b) and expressed in Escherichia coli BL21
(DE3), and they were purified using Ni-NTA affinity chromatography and verified as
the right protein. Lanes 1, 2, and 3 represent S100A9 before purification and lanes 4, 5,
and 6 after purification.

Figure 2. Figures related to the standard curve (A), melting curve of occludin (B), and melting curve of GAPDH (C). Temperature
melting values for PCR products of GAPDH (internal control) and PCR products of occludin were 89.3 °C and 82.88 °C,
respectively. For obtaining the standard curve, several samples were mixed together and serial dilution was conducted (0.01, 0.1,
1, 10, and 100). The standard curve was drawn for both the sample and control. The melting curve showed that there existed no
none-specific product, contamination, and primer dimer.

recombinant S100A9, with IC50 values of 12.5, 6.9, and
5.3 µM after treatment for 24, 48, and 72 h, respectively.
Previously, we assessed calprotectin subunits S100A8
and S100A9 and their physicochemical properties such
as interaction with tyrosinase (Nemati Niko et al., 2017).
S100A9 inhibits tyrosinase, which is overexpressed in
melanomas. This inhibitory effect of S100A9 on tyrosinase
is consistent with the inhibitory effects of other aromatic
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compounds on tyrosinase and proliferation of A-375
melanoma cells (Gheibi et al., 2015). There are many
investigations that emphasize S100A8/A9 subunits as
molecular targets and important biological markers of
cancer and inflammatory studies. The S100A8 and S100A9
subunits are targets of protumorigenic and proapoptotic
signaling pathways and activate many downstream effector
genes that promote tumor progression (Ang et al., 2010).

NAJAFI et al. / Turk J Biol

Figure 3. By increasing the S100A9 concentration and incubation time, OCLN gene
expression was decreased. Change fold values were obtained from qRT-PCR for OCLN
gene expression and compared with control GAPDH before and after treatment with
various concentrations of S100A9. The results of qRT-PCR showed that the effect of
S100A9 on gene expression in the human melanoma cell line was dose-dependent. A a
high dose and a long time, OCLN gene expression was decreased in the melanoma cell
line.

Figure 4. Methylation status of the OCLN gene promoter. M1 and U1 are related to
the reactions in which the target gene primers were used in the methylated and
unmethylated state. M2: Control positive for methylation primer; U2: control positive
for unmethylated primer.

Expression of S100A8 and S100A9 is downregulated
in some tumors, including squamous cell carcinomas
of the head and neck and of the esophagus (Ghavami et
al., 2008). Previous studies have shown that S100A8 and
S100A9 exert dose-dependent effects on cell proliferation.

Low concentrations of S100A8 and S100A9 promote
proliferation, migration, and angiogenesis, whereas high
concentrations of S100A9 exert a proapoptotic effect on
vascular endothelial cells (Li et al., 2012). Stable expression
of calprotectin subunits in HeLa-KB cells suppresses
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Figure 5. Methylation status of the OCLN gene promoter in A-375 melanoma cells
treated with or without different concentrations of S100A9. M1 and U1: Related DNA
methylation status in melanoma cell line after 48 h when treated with S100A9 protein.
M2 and U2: Related DNA methylation status in melanoma cell line after 72 h when
treated with S100A9 protein. M3, M4 and U3, U4: Control without treatment at 48 and
72 h, respectively.

carcinoma growth in vivo and in vitro by restoring the
G2/M cell cycle checkpoint (Chen et al., 2014). Moreover,
silencing of endogenous S100A8 and S100A9 expression
in HNSCC cells increases in vitro tumor growth and
transformation (Rezaei-Tavirani et al., 2008). Knockdown
of S100A9 with siRNA inhibits metastasis and migration
in gastric cancer cells (Turovskaya et al., 2008). In line with
the above studies, melanoma cell line (A-375) treatment
with recombinant S100A9 in this study inhibited the cell
proliferation in a time- and concentration-dependent
manner. As mentioned in Section 1, S100A9’s external
impact on cancer cell line should be implemented by
its binding to three types of receptors, RAGE, TLRs,
and EMMPRIN. The interaction between RAGE and
various ligands such as HMGB1 (high mobility group
box 1) protein activated the nuclear factor kappa-lightchain enhancer of activated B-cells, promoting cellular
proliferation, invasion, and metastasis (Turovskaya et
al., 2009; Nguyen et al., 2017). Ichikawa et al. (2011)
showed that S100A8 and S100A9 interact with RAGE to
activate MAPK and NF-kB signaling pathways. NF-kB is
a critical link between inflammation and cancer (Ichikawa
et al., 2011). Moreover, S100A9 is a novel NF-kB target
protein in hepatic carcinoma cells during inflammationmediated liver carcinogenesis (Németh et al., 2009). An
important aspect of brain metastasis is the migration
of cancer cells through the blood–brain barrier. TJs
between cells play an essential role in keeping cells bound
together. Occludin is an important protein involved in the
generation of TJs. Any disruption in the TJ or occludin
structure (through mutation, methylation, decreased
gene expression, etc.) disrupts the cells and probably their
migration (Simona et al., 2014). The results of qRT-PCR
in Figure 3 show that OCLN gene expression decreased
in A-375 melanoma cells after treatment with different
concentrations of S100A9. According to these results, the
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MTT assay confirmed the qRT-PCR data. It was shown
that treatment of the melanoma cell line with S100A9 was
time- and dose-dependent such that increasing the time
and concentration of incubation decreased the occludin
expression. As mentioned in Section 1, occludin has a
pivotal role in the stabilization of the cellular connection
and inhibition of apoptosis in natural cells (Beeman et
al., 2012). Here, the expression of occludin in the A-375
melanoma cell line decreased under treatment with
S100A9, and this may lead to the induction of apoptosis
and reduced cell viability. Meanwhile, previous studies
showed that decrease of occludin expression resulted in
induction of metastasis in a melanoma cell line (Tracey
et al., 2010). Thus, occludin, as an important component
of TJ proteins, may be used as a target for therapeutic
interventions. It should also be noted that method used
in this study for the surveying of promoter methylation
status was qualitative. In Figures 4 and 5, the MSP-PCR
method shows that the OCLN gene promoter in the A-375
cell line was semimethylated. This method only indicates
the presence or absence of methylation. Therefore, the
modification of the methylation pattern before and after
treatment could not be in conflict with the results of MTT
and qRT-PCR.
In conclusion, S100A9 treatment of the A-375
melanoma cell line reduced the cell proliferation and
OCLN gene expression. The roles of S100A9 need more
investigation to clarify its mechanistic effects on anticancer
and metastatic processes and in particular it could be
an important link and a good crosstalk factor between
inflammation and cancer.
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